STUDY OF THE PATHOGENETIC CHARACTERISTICS AND CLINICAL SIGNIFICANCE OF VISFATIN AND FOLLISTATIN LEVELS IN ENDOCRINE INFERTILITY

Abstract

Objective: This study aimed to evaluate the role of neohormones in the development of endocrine infertility in women with overweight and grade I–II obesity, and to determine the relationship between metabolic disturbances, hormonal imbalance, and impaired reproductive function. The relevance of the research is driven by the increasing prevalence of obesity among women of reproductive age and the limited understanding of how neohormones contribute to the pathogenesis of endocrine infertility. Materials and Methods: The study included 114 women with reproductive dysfunction and varying degrees of excess body weight. Clinical assessment, evaluation of hormonal profiles, analysis of carbohydrate and lipid metabolism, and examination of liver function were performed. Levels of neohormones, including leptin, adiponectin, and several metabolically active peptides, were determined using standard laboratory methods. Results: Significant differences in metabolic parameters were identified, reflecting the extent of adipose tissue dysfunction and disturbances in neuroendocrine regulation. Elevated leptin levels and reduced adiponectin concentrations were associated with markers of insulin resistance, increased liver enzyme activity, and an unfavorable lipid profile. Women with pronounced alterations in neohormone secretion more frequently exhibited anovulatory cycles and a reduced ovarian reserve. These findings confirm the critical role of metabolic disturbances in the development of endocrine infertility among women with obesity. Novelty: The study establishes a comprehensive relationship between neohormone levels, metabolic status, and reproductive dysfunction in women with obesity. The results expand current knowledge of the mechanisms underlying infertility in the context of metabolic disorders and highlight the potential diagnostic value of neohormones as biomarkers. Conclusion: The findings emphasize the importance of routine monitoring of metabolic and hormonal status, including neohormone assessment, in women with obesity and reproductive disorders. An integrated approach to diagnosing and correcting endocrine abnormalities may improve the effectiveness of infertility treatment and enhance reproductive outcomes.